Emyria Limited announce that participant dosing of EMD-RX5 is complete. A final data report is due next month. Emyria's EMD-RX5 capsules were uniquely developed to: Meet FDA requirements for ingredient purity by using ultra-pure CBD, Improve the bioavailability of CBD, Create a palatable dose form for patients As a result, Emyria believes EMD-RX5 has the potential to address multiple clinical indications as a registered medicine where low doses of CBD appear to be effective.

Emyria is initially targeting the registration of EMD-RX5 with Australia's Therapeutic Goods Administration (TGA) as an over-the-counter (Schedule 3) treatment for the symptoms of psychological distress before commencing other registration programs with the same dose form. The symptoms of psychological distress can present as sleep disturbance, gastrointestinal upset and mild anxiety. These symptoms are estimated to affect about 15% of the adult population with a higher prevalence in patients with chronic disease.

There is currently no over-the-counter treatment available for the symptoms of psychological distress. A pivotal Phase 3 clinical trial to support the registration of EMD-RX5 has been planned and is expected to commence immediately following the successful completion of the Phase 1 study. Leading Contract Research Organisation (CRO) and Site Management Organisation (SMO), Clinitrials, have recently been appointed to manage the Pivotal Phase 3 across 5-6 sites in Australia.